


## A SYNTHESIS OF THE C16-C23 SEGMENT OF FK-506


Michael Stocks and Philip Kociński\*  
Chemistry Department, The University, Southampton, SO9 5NH, UK

David K. Donald  
Fisons Pharmaceuticals, Bakewell Road, Loughborough, Leicestershire, LE 11 0RH, UK

**Abstract.** A copper-catalysed migratory insertion reaction was used to construct the tri-substituted alkene of the C16-C23 segment 4 of the potent immunosuppressant FK-506 (Tsukubaenolide) (1).


Cyclosporin has been an essential factor in the progress of transplant surgery in the past decade<sup>1</sup>. However, its nephrotoxicity and other limitations have stimulated a search for alternative agents. One such agent is FK-506 (tsukubaenolide) (1), a macrolide isolated from *Streptomyces tsukubaensis* by a Japanese group<sup>2</sup> in 1984, and shown to be immunosuppressive *in vitro* by Kino and co-workers<sup>3</sup> in 1987. Numerous reports soon validated the potential of FK-506 for immunosuppression *in vivo*<sup>4</sup>. Most dramatic of all, however, were the results communicated in *The Lancet* on October 28, 1989: FK 506 was successfully administered to human patients in desperate plight because their liver grafts were being rejected despite conventional immunosuppression<sup>5</sup>. Interest in FK-506 is now intense and a spate of papers has appeared recently recording a total synthesis<sup>6</sup> as well as syntheses of various segments<sup>7</sup>. Preliminary studies on the potential mode of action have also appeared<sup>8</sup>. We now report a synthesis of the C16-C23 segment 4 which complements the syntheses of the C1-C15 segment 2 and the C24-C34 segment 3 previously disclosed<sup>9,10</sup>. A salient feature of our synthesis of segment 4 is the stereoselective construction of the tri-substituted alkene using a novel copper-catalysed migratory insertion reaction.





Our synthesis began (Scheme 1) with (+)-tartaric acid which was converted to the oxiran **5** in 73% overall yield according to known procedures<sup>11</sup>. Nucleophilic scission of the oxiran ring with allylmagnesium bromide gave the alcohol **6** from which the benzyl protecting groups were removed using dissolving metal reduction. The resultant triol was not purified owing to high water solubility; consequently, the crude triol was converted to the acetone **7** in 63% overall yield in the usual way. The alcohol function in **7** was converted to the corresponding *p*-toluenesulphonate ester which underwent nucleophilic displacement with cyanide to give the nitrile **8** in 75% overall yield from **7**. Hydrolysis of the acetone and cyano functions and lactonisation were all accomplished in a single operation on treatment of nitrile **8** with HCl in MeOH. After protection of the primary hydroxyl function as the *t*-butyldimethylsilyl ether, the lactone carbonyl in **10** was reduced with diisobutylaluminium hydride. The resultant mixture of diastereoisomeric lactols was then dehydrated *via* the methanesulphonate ester. Attempts to eliminate the methanesulphonate in dichloromethane under a variety of conditions proceeded in poor yield. However, by using tetrahydrofuran as solvent the elimination reaction was clean and efficient affording the desired homochiral dihydrofuran **11** in 86% overall yield from lactone **10**.

The key step in our synthetic plan (Scheme 2) was a migratory insertion of the higher order cuprate<sup>12,13</sup> intermediate **16** prepared by reaction of the lithiated dihydrofuran **12** with the homocuprate **15**. As expected from earlier studies, the migratory insertion of **16** took place with clean inversion of stereochemistry to give the putative higher order oxycuprate **17**. Intermediate **17** underwent alkylation with retention of configuration at low temperature to give the tri-




substituted alkene **18** in 57% overall yield from **11**. Considerable effort was expended to ascertain the optimum conditions for achieving the requisite rearrangement. The principal problems were the thermal instability of the cuprate **15** versus the relatively high temperature (35°C)<sup>14</sup> required for the migratory insertion. These were eventually reconciled by adding dimethyl sulphide to the reaction mixture to stabilise the cuprate **15**. The critical experimental procedure is detailed below:

To a magnetically stirred solution of (2R)-2-methyl-3-*t*-butoxy-1-iodopropane **13** (396 mg, 1.55 mmol) in Et<sub>2</sub>O (3 ml) at -78°C was added *t*-BuLi in pentane (1.7 M, 1.55 ml, 2.64 mmol). The mixture was warmed to 0°C and stirred for 10 min whereupon THF (0.5 ml) was added dropwise to destroy excess *t*-BuLi. After 20 min at 0°C, the mixture was cooled to -78°C and a solution of CuBr·SMe<sub>2</sub> (160 mg, 0.775 mmol) in SMe<sub>2</sub> (2 ml) was added dropwise. The mixture was allowed to slowly warm to room temperature during which time the mixture became a homogeneous yellow solution (at ca. -20°C). The mixture was then heated to reflux whilst a solution of the lithiated dihydrofuran **12** [prepared in Et<sub>2</sub>O from 100 mg (0.388 mmol) of **11** and 1.1 eq of *t*-BuLi] was added dropwise. After addition was complete the mixture was heated under reflux for 30 min and then cooled to -78°C whereupon HMPA (95 µl, 0.775 mmol) was added followed by MeI (177 mg, 1.16 mmol). The mixture was then stirred at -40°C for 1 h and allowed to attain room temperature over 1 h. The reaction mixture was poured into saturated aqueous NH<sub>4</sub>Cl and the product extracted into Et<sub>2</sub>O. The extract was dried over MgSO<sub>4</sub>, concentrated *in vacuo*, and the residue purified by column chromatography on silica gel 60 eluting with 5% Et<sub>2</sub>O in hexane to give **18** (89 mg, 57%) as a colourless oil: [α]<sub>D</sub> -5.8° (c. 2 in CHCl<sub>3</sub>); IR (film) 3473 br, 2956 s, 2858 s, 1640 w, 1472 m, 1362 m, 1254 m, 1198 m, 1081 s, 836 s cm<sup>-1</sup>; <sup>1</sup>H NMR (270 MHz, CDCl<sub>3</sub>) 5.76 (1H, dddd, J = 17, 10, 7, 7 Hz), 5.1(1H, d, J = 10 Hz), 5.03 (1H, d, J = 17 Hz), 4.96 (1H, d, J = 10 Hz), 3.4-3.7 (3H, m), 3.17 (1H, dd, J = 8.5, 3 Hz), 3.08 (1H, dd, J = 7.5, 7.0 Hz), 2.56-2.43 (1H, m), 2.4-2.0 (4H, m), 1.9-1.6 (2H, m), 1.58 (3H, s), 1.17 (9H, s), 0.90 (9H, s), 0.82 (3H, d, J = 6.4 Hz), 0.04 (6H, s); <sup>13</sup>C NMR (67.9 MHz, CDCl<sub>3</sub>) 137.3 (d), 136.3 (s), 125.6 (d), 115.9 (t), 74.3 (d), 72.5 (s), 67.5 (t), 65.9 (t), 44.7 (t), 40.4 (d), 36.8 (t), 32.1 (d), 27.8 (q), 26.5 (q), 26.0 (q), 18.1 (s), 17.0 (q), 16.7 (q), 4.24 (q); LRMS (CI mode, NH<sub>3</sub>): m/z 399 (M+1)<sup>+</sup>, 343 (100), 211 (44), 193 (63), 99 (67).

To complete the synthesis (Scheme 3), the protecting group was removed from **18** and the resultant diol selectively converted to the terminal methanesulphonate ester. On treatment with potassium carbonate in MeOH, this was converted in high yield to the oxiran **19**. Reductive opening of the oxiran ring in **19** occurred regioselectively to afford the alcohol **20** which underwent smooth oxidation to the desired ketone **4** using the Dess-Martin reagent<sup>15</sup>. Under these conditions the product **4** was obtained efficiently without racemisation<sup>16</sup>.

In conclusion, we have demonstrated the value of copper-catalysed migratory insertion chemistry for the elaboration of polyketide chains incorporating tri-substituted alkenes flanked by stereogenic centres. Efforts are now underway to link segments **2**, **3**, and **4** or derivatives thereof and thus accomplish a total synthesis of FK-506.



**SCHEME 3. Yields and Reagents:**

- a 97% TBAF / THF  
 b 91% (i) MsCl / Et<sub>3</sub>N-THF, -70 to 20°C; (ii) K<sub>2</sub>CO<sub>3</sub> / MeOH  
 c 98% LiAlH<sub>4</sub> / THF  
 d 92% Dess-Martin oxidation

**Acknowledgements.** We thank the Science and Engineering Research Council, the Wolfson Foundation, and Fisons Pharmaceuticals for financial support. This is a contribution from the Southampton University Institute of Biomolecular Science.

#### References and Notes

- Wenger, R. M. *Angew. Chem. Int'l Ed. Engl.*, **1985**, *24*, 77; *Cyclosporin, Progress in Allergy 38*; Borel, J. F., Ed.; Karger: New York, 1986.
- Tanaka, H.; Kuroda, A.; Marusawa, H.; Hatanaka, H.; Kino, T.; Goto, T.; Hashimoto, M.; Taga, T. *J. Am. Chem. Soc.*, **1987**, *109*, 5031 and references therein.
- Kino, T.; Hatanaka, H.; Miyata, S.; Inamura, N.; Yajima, T.; Goto, T.; Okuhara, M.; Kohsaka, M.; Aoki, H.; Ochiai, T. *J. Antibiotics*, **1987**, *40*, 1256.
- Starzl, T. E.; Makowka, L.; Todo, S. (eds.), *Transplant, Proc.*, **1987**, *19* (suppl 6): 3-104.
- Starzl, T. E.; Fung, J.; Venkataraman, R.; Todo, S.; Demetris, A. J.; Jain, A. *Lancet*, **1989**, 1000.
- Jones, T. K.; Mills, S. G.; Reamer, R. A.; Askin, D.; Desmond, R.; Volante, R. P.; Shinkai, I. *J. Am. Chem. Soc.*, **1989**, *111*, 1157.
- (a) Williams, D. R.; Benbow, J. W. *J. Org. Chem.*, **1988**, *53*, 4643.  
(b) Schreiber, S. L.; Smith, D. B. *J. Org. Chem.*, **1989**, *54*, 9.  
(c) Egbertson, M.; Danishefsky, S. J. *J. Org. Chem.*, **1989**, *54*, 11.  
(d) Villalobos, A.; Danishefsky, S. J. *J. Org. Chem.*, **1989**, *54*, 12.  
(e) Schreiber, S. L.; Sammakia, T.; Uehling, D. E. *J. Org. Chem.*, **1989**, *54*, 15.  
(f) Jones, A. B.; Yamaguchi, M.; Patten, A.; Danishefsky, S. J.; Ragan, J. A.; Smith, D. B.; Schreiber, S. L. *J. Org. Chem.*, **1989**, *54*, 19.  
(g) Ireland, R. E.; Wipf, P. *Tetrahedron Lett.*, **1989**, *30*, 919.  
(h) Smith, A. B.; Hale, K. J. *Tetrahedron Lett.*, **1989**, *30*, 1037.  
(i) Wasserman, H. H.; Rotello, V. M.; Williams, D. R.; Benbow, J. W. *J. Org. Chem.*, **1989**, *54*, 2785.  
(j) Corey, E. J.; Huang, H.-C.; *Tetrahedron Lett.*, **1989**, *30*, 5235.  
(k) Wang, Zhaoyin *Tetrahedron Lett.*, **1989**, *30*, 6611.  
(l) Smith, A. B.; Hale, K. J.; Laakso, L. M.; Chen, K.; Riera, A. *Tetrahedron Lett.*, **1989**, *30*, 6963.
- Siekierka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H. *Nature*, **1989**, *341*, 755; Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiber, S. L. *Nature*, **1989**, *341*, 758.
- Kociński, P.; Stocks, M.; Donald, D.; Cooper, M.; Manners, A. *Tetrahedron Lett.*, **1988**, *29*, 4481.
- Kociński, P.; Stocks, M.; Donald, D.; Perry, M. *Synlett*, **1990**, 31.
- Wenger, R. M., *Helv. Chim. Acta*, **1983**, *66*, 2308.
- Kociński, P.; Wadman, S.; Cooper, K. *J. Am. Chem. Soc.*, **1989**, *111*, 2363.
- Kociński, P.; Dixon, N. J. *Synlett*, **1989**, 52.
- We thank Mr. Christopher Barber for demonstrating the crucial significance of reaction temperature in copper-catalysed migratory insertion reactions involving dihydrofurans.
- Dess, D. B.; Martin, J. C. *J. Org. Chem.*, **1983**, *46*, 4155.
- Spectroscopic data for ketone **4**:  $[\alpha]_D^{25} -128.8^\circ$  [c. 0.132 in  $\text{CHCl}_3$ ]; IR (film) 3078 w, 2973 s, 2926 s, 1715 s, 1642 m, 1440 m, 1362 s, 1198 s, 1080 s, 914 m  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (270 MHz,  $\text{CDCl}_3$ ) 5.68 (1H, dddd, J = 16.9, 9.9, 6.75, 6.75 Hz), 5.02 (1H, d with further fine splitting, J = 16.9 Hz), 4.95 (2H, 2 overlapping d, J = 9.9 Hz), 3.36 (1H, ddd, J = 7.0, 5.9, 5.9 Hz), 3.13 (1H, dd, J = 7.0, 3.5 Hz), 3.04 (1H, dd, 7.0, 5.8 Hz), 2.42 (1H, ddd, J = 11.2, 5.6, 5.6 Hz), 2.21-2.16 (2H, m), 2.08 (3H, s), 1.82-1.68 (2H, m), 1.66 (3H, s), 1.14 (9H, s), 0.80 (3H, d, J = 6.4 Hz);  $^{13}\text{C}$  NMR (67.9 MHz,  $\text{CDCl}_3$ ) 209.1 (s), 138.6 (s), 135.9 (d), 123.6 (d), 116.5 (t), 72.4 (s), 67.0 (t), 53.0 (d), 44.5 (t), 35.8 (t), 32.0 (d), 28.6 (q), 27.7 (q), 17.1 (q), 16.7 (q); LRMS (CI mode,  $\text{NH}_3$ ) 267 (M+1)<sup>+</sup> (3%), 211 (100), 193 (16), 151 (18), 149 (28), 108 (27), 99 (18).